Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.53 – $2.64
46% from low
Borrow rate
12.73%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.5M | $0 | $2.6M | $3.5M |
| Gross profit | −$1.5M | $0 | −$2.6M | −$3.5M |
| Gross margin | — | — | — | — |
| R&D | $159.8M | $167.2M | $162.0M | $110.7M |
| Operating income | −$175.4M | −$184.9M | −$194.6M | −$138.3M |
| EBITDA | −$173.9M | −$183.4M | −$192.7M | −$125.0M |
| Net income | −$175.4M | −$189.8M | −$207.4M | −$128.5M |
| Net margin | — | — | — | — |
| EPS (diluted) | -10.51 | -11.37 | -12.43 | -7.58 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-0.39 | $-0.39–$-0.39 | 1 |
| 2027 | $22M | $-0.12 | $-0.12–$-0.12 | 1 |
| 2028 | $97M | $0.34 | $0.34–$0.34 | 1 |
| 2029 | $97M | $-1.45 | $-1.45–$-1.45 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds MURA.
No tracked institution reports a position in MURA as of their last filing.
No one on the platform has traded MURA yet.
| $20M |
| — |
| GBIOGeneration Bio Co. | $5.34 | +0.00% | $36M | — |
| JSPRJasper Therapeutics, Inc. | $0.42 | +23.11% | $7M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$MURA Review Alejos here. 🫨 https://www.trustpilot.com/review/www.jccapitalconsultants.com
View on StockTwits ↗$MURA Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition https://www.globenewswire.com/news-release/2025/12/05/3200635/0/en/Mural-Oncology-Announces-Effectiveness-of-Scheme-of-Arrangement-and-Completion-of-Acquisition.html
View on StockTwits ↗$MURA Announces Sanction of the Scheme by the High Court https://www.globenewswire.com/news-release/2025/12/03/3199385/0/en/Mural-Oncology-Announces-Sanction-of-the-Scheme-by-the-High-Court.html Delivery of the Court Order to the Irish Registrar of Companies is expected to occur, and the Acquisition is expected to become effective, on 5 December 2025 (the “Effective Date”). Accordingly, 4 December 2025 is expected to be the last date on which trading of Mural Shares on the Nasdaq will occur. Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market is expected to occur with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025.
View on StockTwits ↗$MURA NASDAQ Equity Corporate Actions Alert # 2025 - 646 (UPDATED: Anticipated Last Trade Date) Information Regarding the Merger of Mural Oncology plc (MURA) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2025-646 At a special meeting held on October 24, 2025, the shareholders of Mural Oncology plc (MURA) approved the proposed merger with XOMA Royalty Corporation (XOMA). The merger is tentatively scheduled to close prior to the market open on December 5, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on December 4, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (December 5th) and will be suspended effective December 8, 2025.
View on StockTwits ↗$MURA / $XOMA - Shareholder Vote $MURA MergerBrief.com For Full Schedule
View on StockTwits ↗$MURA Excellent article that nails exactly where MURA stands right now. So if you want to update your MURA knowledge or get acquainted with MURA, this is a must read. https://beyondspx.com/quote/MURA/analysis/mural-oncology-a-biotech-pivot-amidst-trial-setbacks-and-strategic-uncertainty-nasdaq-mura
View on StockTwits ↗EOD FOLLOW-UP - 08/20/25 Tracking continuation watchlist from today based on intraday highs vs. close ❌ $CLNN - Closed 5.66, HOD 5.59 (–1.2%) Failed to push, straight fade. ❌ $MURA - No volume, no movement. ❌ $COCH - No volume, no movement. ✅ $NESR - Closed 8.31, HOD 8.81 (+6.0%) Brief pop, then dancing around the VWAP ❌ $GES - No volume, no movement. Recap: 5 total, 1 winners, 4 fails → 20% accuracy Almost no continuation strength today. $NESR gave a small pop but couldn’t hold, while $CLNN, $MURA, $COCH, and $GES showed no traction. #VWAP #SmallCaps #DayTrading #EODFollowUp #Continuation #SniperSetup #Accountability
View on StockTwits ↗$MURA Congrats to the clowns who bought this over $2 . You are the proud new owners of $XOMA another failed biotech that’s down 99% since IPO. 😂🤣🤣. Tried to warn you clowns you were falling for an Irish scam. Closed out my short last week , just had to rub it in for the dudes who were calling me low IQ and retarded🤡🤡
View on StockTwits ↗EOD CONTINUATION WATCHLIST - 08/20/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $CLNN - 3.5x volume, 7.4% VWAP stretch, micro float. 19.2% open-to-current with 1.3% late push, RSI 54.2. Needs breakout over 5.62+ for continuation. $MURA - 5.8x volume, 0.6% VWAP stretch, small float. 1.5% open-to-current with 0.2% late push, RSI 55.9. Needs breakout over 2.10+ for continuation. $COCH - 9.8x volume, 2.2% VWAP stretch, small float. 1.6% open-to-current with 2.4% late push, RSI 53.7. Needs breakout over 1.27+ for continuation. $NESR - 2.5x volume, 0.5% VWAP stretch, small float. 5.1% open-to-current with 1.0% late push, RSI 61.8. Needs breakout over 8.50+ for continuation. $GES - 7.6x volume, 0.1% VWAP stretch, small float. 0.2% open-to-current with 0.1% late push, RSI 48.5. Needs breakout over 16.85+ for continuation. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups #PowerHourWatch
View on StockTwits ↗Mural Oncology To Be Acquired By Xoma Royalty $MURA $XOMA https://stocktwits.com/news/equity/markets/mural-oncology-to-be-acquired-by-xoma-royalty/chsioLsRdhL
View on StockTwits ↗$MURA (halted pre) 98% Premium: $XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal https://ooc.bz/l/74570
View on StockTwits ↗$MURA Further clarification on the BO price. Base price of $2.035 per share is based on MURA having $36.2m in Closing Net Cash at the closing date. If MURA has more than $36.2m at closing, the excess will be distributed to shareholders. Distribution of excess cash is capped at a maximum of $0.205 per share. If MURA has less than $36.2m at closing, then shareholders will only receive the base price of $2.035 per share.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.